The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

Out of the 43 analysts that now have coverage on HUL, 27 of them have maintained a 'Buy' rating on the stock, while 13 of ...

Taking a more bearish stance, CLSA has downgraded HUL to an Underperform rating. The brokerage firm also has slashed its ...

There is mild anticipation that as the Snake year slithers in, the local IPO markets will open up, and the STI will hit a new ...

Donald Trump's return as president, Union Budget, first policy meeting under the Reserve Bank of India's new governor are key ...

SK Hynix Inc. reported a record quarterly profit after the company extended its lead in advanced memory chips for datacenters ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 15.45% ...

India's most valued company, Reliance Industries Ltd (RIL), reported a robust performance in the third quarter of the current ...